Neoantigen: A New Hope for Effective Cancer Immunotherapy
DOI:
https://doi.org/10.17140/VROJ-4-113Abstract
In recent years, immunotherapy with the aim of augmenting the body's immune system to recognize and destroy tumor cells has been widely investigated as a novel cancer therapy modality. Immune responses can be naturally generated against cancer cells. On the other hand, cancer cells can inhibit anticancer immune responses. In the past decades, vaccination with tumor specific associated antigens and immunogenic vectors has been successfully used to increase antitumor immune responses. However, the choice of target antigen is imperative in designing a cancer vaccine.
References
Schumacher TN, Schreiber RD. Neoantigens in cancer immu-notherapy. Science. 2015; 348(6230): 69-74. doi: 10.1126/science. aaa4971
Srivastava PK. Neoepitopes of cancers: looking back, looking ahead. Cancer Immunol Res. 2015; 3(9): 969-977. doi: 10.1158/2326- 6066
Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016; 4: 3. doi: 10.1186/s40425-016-0107-3
Ma W, Gilligan, BM, Yuan J, Li T. Current status and perspec-tives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016; 9(1): 47. doi: 10.1186/s13045-016-0277-y
Leko V, McDuffie LA, Zheng Z, et al. Identification of neo-antigen reactive tumor infiltrating lymphocytes in primarybladder cancer. J Immunol. 2019; 202(12): 3458-3467. doi: 10.4049/jimmu-nol.1801022 Submit your article to this journal | https://openventio.org/submit-manuscript/ 20 Khansari N
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regres-sion and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594): 850-854. doi: 10.1126/science.1076514
Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myelo-ablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26(32): 5233-5239. doi: 10.1200/JCO.2008
van Roji N, van Burren MM, Philips D, et al. Tumor exome analysis reveals neoantigen specific T-cell reactivity in an ipilimum-ab-responsive melanoma. J Clin Oncol. 2013; 31(32): e439-e442. doi: 10.1200/JCO.2012.47.7521
Linnemann C, van Burren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015; 21(1): 81-85. doi: 10.1038/nm.3773
Lu YC, Yao X, Crystal JS, et al. Efficient identification of mu-tated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20(13): 3401-3410. doi: 10.1158/1078-0432
Rahma OE, Hamilton JM, Wojtowicz M, et al. The immuno-logical and clinical effects of mutated Ras peptide vaccine in com-bination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014; 12:55. doi: 10.1186/1479-5876-12-55
Chheda ZS, Kohanbash G, Okada K, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018; 215(1): 141-157. doi: 10.1084/jem.20171046
Deniger DC, Pasetto A, Robbins PF, et al. T-cell responses to TP53 “hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018; 24(22): 5562-5573. doi: 10.1158/1078-0432
Ott PA, Hu Z, Keskin DB, et al. An immunogenic person-al neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662): 217-221. doi: 10.1038/nature22991 Opinion | Volume 4 | Number 1|
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.